Therapeutic role of granulocyte colony-stimulating factor (G-CSF) for infertile women under in vitro fertilization and embryo transfer (IVF-ET) treatment: a meta-analysis

Ling Zhang1 • Wei-Hai Xu1 • Xiao-Hua Fu1 • Qiong-Xiao Huang1 • Xiao-Yan Guo1 • Lin Zhang1 • Shi-Shi Li1 • Jing Zhu1 • Jing Shu1

Received: 5 July 2018 / Accepted: 6 September 2018 / Published online: 15 September 2018 © The Author(s) 2018

Abstract
Objective The aim of this meta-analysis is to explore the beneficial role of granulocyte colony-stimulating factor (G-CSF) on infertile women under artificial reproduction technology treatment.
Method Medline, Embase and ISI Web of Science databases were searched to identify relevant randomized control trials. Studies before July, 2017 were included for primary screening. Meta-analysis of the total and subgroup patients was conducted, and relative risks (RRs) and their 95% confidence intervals (95% CI) were calculated by a fixed-effect model if no heterogeneity (evaluated as \(I^2\) statistic) existed. Otherwise, a random-effects model was adopted. Subgroup analysis was performed by administrating route or clinical indication. Egger test and influence analysis were conducted to evaluate the publication bias and study power, respectively.
Results The final selection enrolled 10 RCTs, involving 1016 IVF-ET cycles (521 distributed to the G-CSF group and 495 to the control). Compared with control group, G-CSF administration could significantly improve clinical pregnancy rate (CPR, RR 1.89, 95% CI 1.53–2.33), while it had no beneficial effect on embryo implantation rate (IR, RR 1.84, 95% CI 0.84–4.03). The subgroup analysis by administration route showed that both uterine infusion and subcutaneous injection can produce a substantial increase in CPR, with the pooled RRs (95% CI) 1.46 (1.04–2.05) and 2.23 (1.68–2.95), respectively. Nevertheless, most of included RCTs dealt with the RIF subjects, and the pooled analysis of this data showed a higher PR and IR in G-CSF group as compared to that in the control, with the RRs (95% CI) 2.07 (1.64–2.61) and 1.52 (1.08–2.14), respectively. Egger regression test did not demonstrate any significance for the publication bias.
Conclusion G-CSF administration has a beneficial role on the clinical outcome after embryo transfer by both routes of local infusion and systematic administration, especially for the cases with RIF. Further RCTs are needed to investigate the role of G-CSF in thin endometrium patients.

Keywords Granulocyte colony-stimulating factor • Embryo transfer • Infertility • Meta-analysis • Repeated implantation failure • Thin endometrium

Introduction
Implantation of a competent blastocyst into receptive endometrium is key to build a successful pregnancy [1]. Despite major advancement in reproductive medicine over the last few decades, implantation failure still makes frequent appearance during the process of assisted reproductive technology (ART) [2, 3]. Repeated implantation failure (RIF), generally defined as failure of three in vitro fertilization and embryo transfer (IVF-ET) cycles in which one or two high-grade quality embryos were transferred to the patient in each cycle [4], represents an enormous emotional and
financial burden for the patient. Poor endometrial receptivity has been generally considered as a major cause of the failure of embryo implantation, and endometrial thickness as an important component of endometrial receptivity [5]. Several therapies have been proposed for solving the problem in endometrial receptivity, such as extended estrogen administration, treatment with low-dose aspirin, vaginal sildenafil citrate, and treatment with pentoxifylline and tocopherol, and proven successful in some cases. However, many cases still remain resistant to these treatments [5].

Successful embryo implantation requires an intricate biological interaction between the implanting embryo and the host endometrium [6]. A bulk of molecular factors have been implicated in this complex process, including endometrial integrins, extracellular matrix molecules, adhesion molecules, growth factors, and ion channels [1]. Granulocyte colony-stimulating factor (G-CSF) belongs to the family of colony-stimulating factors (CSF) synthesized by multiple cell types (e.g., endothelial cells, fibroblasts, macrophages, lymphocytes) [7, 8], and has been proven to originate from some reproductive tissue cells as well, such as human ovary [9] and endometrium [10]. Particularly, some pieces of evidence have showed that G-CSF or its receptor be located in luteinized granulosa cells, placenta trophoblastic cell and oocytes [11–13]. Currently, several physiological roles have been suggested for G-CSF during the process of pregnancy forming, i.e., promoting embryo cleavage and blastocyst formation [13], regulating endometrial expressions crucial for a series of implantation processes including endometrial vascular remodeling, local immune modulation and cellular adhesion pathways [14], and targeting follicle development and ovulation [15].

The therapeutic effect of G-CSF in patients with RIF has been investigated as early as 2000 by Würfel and the colleagues, and the results show that systematic administration of G-CSF is able to enhance the implantation rate dramatically [16]. Since then, bulks of similar studies have been conducted for RIF cases due to poor endometrial thickness or other reasons, but the conclusions are inconsistent. Even in rigorously randomized control trials (RCTs), only about half reach a conclusion that G-CSF can improve the endometrium thickness, implantation rate or clinical pregnancy rate after IVF treatment [16–18], while the remains negative [19–23]. This inconsistence might be owing to the heterogeneity in administration route or clinical conditions between studies. Indeed, currently published studies were structured into various designs, such as randomized control trials (RCTs), observational studies, self-controlled trials or single arm studies; included subjects of different clinical conditions including RIF, thin endometrium or unselected patients, and did not adapt the same administration route, systematic injection or intrauterine infusion.

Single study may be limited by sample size, research design, administration route, clinical conditions, or patient’s ethnicity and age, and underpowered to achieve a comprehensive and reliable conclusion. Meta-analysis has the benefit to overcome this limitation by increasing the sample size. Therefore, this study was designed to explore the efficacy of G-CSF on infertile patients undergoing IVF-ET treatment with RIF.

Methods and procedures

The review protocol was registered in PROSPERO (CRD42018056662). Randomized controlled trials (RCTs) comparing G-CSF treatment versus the control were included in this meta-analysis. Pseudo-randomized trials were excluded.

We collected the relevant studies by searching the databases of Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase and ISI Web of Science updated in July, 2017, using the keywords: (‘Granulocyte colony stimulating factor’ OR ‘Granulocyte Colony-Stimulating Factor’ OR ‘G-CSF’ OR ‘CSF’) AND (‘Assisted Reproductive Techniques’ OR ‘ART’ OR ‘In Vitro Fertilization’ OR ‘IVF’ OR ‘Intracytoplasmatic Sperm Injection’ OR ‘ICSI’ OR ‘embryo transfer’ OR ‘FET’). There were no limitations on the type of the publication. All languages were accepted. We also searched for study protocols and ongoing trials in ClinicalTrials.gov (https://clinicaltrials.gov/). References of retrieved articles were also screened.

Our primary outcome measure was clinical pregnancy rate (CPR) per woman randomly assigned, and the secondary one implantation rate (IR) per embryo transferred. All literatures were reviewed independently by two authors. The flow chart for study selection was shown in Fig. 1. Two authors extracted data independently and in duplicate, and reached on all items including author’s last name, journal and year of publication, country of origin, ethnicity of the patients, definition of RIF or thin endometrium, count of each event in GSF group and the control. The results were compared and disagreements were discussed and resolved with consensus.

Risk of bias in individual study was structured using the Cochrane risk of bias assessment tool to assess: selection (random sequence generation and allocation concealment); performance (blinding of participants and personnel); detection (blinding of outcome assessors); attrition bias (incomplete outcome data); reporting bias (selective outcome reporting) and other potential sources of bias. The trials were classified as being at ‘low’, ‘high’ or ‘unclear’ risk of bias.

The pooled RRs and their 95% confidence interval (CI) were estimated to assess the role of G-CSF treatment on the outcomes of IVF-ET. The pooled RRs were calculated
through a Mantel–Haenszel fixed effects model if there was no heterogeneity. Otherwise, a random-effects model was adopted. Subgroup analysis was performed by administration route and clinical indications. Statistical heterogeneity across studies was formally tested using Cochran’s test. The $I^2$ statistic was examined and $I^2 > 50\%$ was considered significant for the heterogeneity between studies. An influence analysis was conducted to describe how robust the pooled estimator is after removal of individual studies. An individual study was suspected of excessive influence if the point estimate of its omitted analysis lies outside the 95\% CI of the combined analysis. Publication bias across studies was assessed using the Egger regression test and Begg’s funnel plot. All analyses were conducted in Stata software (Version 14.0; Stata Corporation, College Station, TX, USA).

**Results**

**Study characteristics**

The last electronic search was conducted in July 25, 2017, retrieving a total of 971 records. After screening the titles and abstracts, we removed 894 records including 609 duplicates and 285 ones that did not meet the eligibility criteria.
Table 1 Characteristics of the studies included in the meta-analysis

| Author, year          | Country    | Period of enrolment       | Publication type | Sample size | Female age (years) CSF/control | Indications                                                                 | Diagnostic criteria                                                                                                                                                                                                 | Inclusion and exclusion criteria                                                                                      |
|-----------------------|------------|---------------------------|------------------|-------------|-------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| Aleyasin A, 2016 [25]| Iran       | March 2015–January 2016   | Origin article   | 112         | 33.5 ± 4.2/32.4 ± 5.2         | RIF                                                                        | Transferred embryos fail to implant after three IVF cycles                                                                                                                                                    | < 40 years, with normal endometrium thickness, and without sensitivity of GCSF, or any systemic disease, or detection of Asherman’s syndrome, fibroids and/or polyps |
| Barad DH, 2014 [19]   | USA        | October 2010–January 2013 | Origin article   | 141         | 39.79 ± 5.13/39.38 ± 6.03     | Unselected                                                                 | –                                                                                                                                                                                                                           | With normal endometrial thickness, and without renal disease, sickle cell disease, or a history of malignancy          |
| Davari-Tanha F, 2016 | Iran       | December 2011–January 2014| Origin article   | 80          | 35.5 ± 4.32/35.3 ± 3.98       | RIF                                                                        | History of three times implantation failure with at least four good-quality embryos                                                                                                                              | < 40 years, without uterine, thrombophilic factors, or history of renal disease, sickle cell disease or malignancy or sensitivity of G-CSF |
| Eftekhar M, 2016 [22] | Iran       | October 2014–February 2015| Origin article   | 90          | 32.55 ± 4.61/31.75 ± 5.16     | RIF                                                                        | At least two implantation failures                                                                                                                                                                | 20–40 years, without sickle cell disease, chronic neutropenia, malignancy history, renal failure, congenital fructose intolerance, respiratory infection, endometriosis, or severe male factor |
| Kim CH, 2011 [30]     | South Korea| NR                        | Meeting abstract | 82          | NR                            | RIF                                                                        | At least three previous failed IVF attempts with good quality embryos                                                                                                                                         | 29–40 years, without thrombophilia or anatomic abnormalities of uterine cavity                                    |
| Obidniak D, 2016,    | Russia     | NR                        | Meeting abstract | 130         | NR                            | RIF                                                                        | At least two previous failed IVF attempts with good-quality blastocysts                                                                                                                                       | 32–40 years, with normal endometrial thickness and availability of vitrified blastocyst, without congenital uterine anomalies or Asherman’s syndrome |
| part I [21]           |            |                           |                  |             |                               |                                                                            |                                                                                                                                      |                                                                                                                        |
| Obidniak D, 2016,    | Russia     | NR                        | Meeting abstract | 130         | NR                            | RIF                                                                        | At least two previous failed IVF attempts with good-quality blastocysts                                                                                                                                       | 32–40 years, with normal endometrial thickness and availability of vitrified blastocyst, without congenital uterine anomalies or Asherman’s syndrome |
| part II [21]          |            |                           |                  |             |                               |                                                                            |                                                                                                                                      |                                                                                                                        |
| Scarpellini F, 2011   | Italy      | NR                        | Meeting abstract | 89          | NR                            | RIF                                                                        | NR                                                                                                                                     | NR                                                                                                                                                                     |
| Scarpellini F, 2012   | Italy      | January 2008–December 2010| Meeting abstract | 109         | NR                            | RIF                                                                        | At least three previous failed IVF attempts with at least seven good embryos                                                                                                                                  | < 39 years, absence of systemic diseases                                                                                                                                  |
| Author, year | Country     | Period of enrolment   | Publication type          | Sample size | Female age (years) CSF/control | Indications | Diagnostic criteria | Inclusion and exclusion criteria |
|--------------|-------------|-----------------------|---------------------------|-------------|--------------------------------|-------------|---------------------|----------------------------------|
| Singh R, 2015 [20] | India       | January 2014–December 2014 | Meeting abstract          | 48          | <40                             | Thin endometrium | NR                  | <42 years                        |
| Würfel W, 2000 [16] | Germany     | NR                    | Meeting abstract          | 138         | NR                             | RIF         | At least three previous failed IVF attempts with at least five embryos and more than 50% embryos transferred in good quality | <40 years, undergoing the fourth or fifth IVF or ICSI cycle |

| Author, year | Drug route/dose | Administration time | Description of the control | Protocol | Embryo age | Previous failure CSF/control | Embryos transferred CSF/control | Good embryos transferred (%) CSF/control |
|--------------|-----------------|---------------------|-----------------------------|----------|------------|-----------------------------|-------------------------------|-----------------------------------|
| Aleyasin A, 2016 [25] | Subcutaneously 300 µg | 1 h before the ET | No therapy                   | Fresh ET | D3         | 3/3                         | 2.3 ± 0.6/2.5 ± 0.6           | NR                                |
| Barad DH, 2014 [19] | Intrauterine infusion 300 µg | The morning of hCG administration | Normal saline               | Fresh or frozen ET | D3 or D5   | NR                         | 2.41/2.47                     | 45.57/39.29                       |
| Davari-Tanha F, 2016 [23] | Intrauterine infusion 300 µg | At the time of oocyte retrieval. In FET cycle, at the day of starting progesterone | Normal saline               | Fresh or frozen ET | D3 or D5   | 3.5±2.1/4.2±1.5          | NR                             | NR                                |
| Eftekhar M, 2016 [22] | Intrauterine infusion 300 µg | At the time of oocyte retrieval | Without GSF infusion        | Fresh ET  | D3         | 2.57±1.69/3.41±1.54       | 2.11/2.35                    | 61.4/57.80                       |
| Kim CH, 2011 [30] | NR 100 µg × 2 | The day of ET and the fourth day after ET | –                           | Fresh ET  | D3         | NR                         | NR                           | NR                                |
| Obidniak D, 2016, part I [21] | Intrauterine infusion 300 µg | 5 days prior to ET, or at the day of ET | No therapy                   | Frozen ET | Blastocyst | NR                         | NR                           | NR                                |
| Obidniak D, 2016, part II [21] | Subcutaneously 300 µg | 5 days prior to ET, or at the day of ET | No therapy                   | Frozen ET | Blastocyst | NR                         | NR                           | NR                                |
| Scarpellini F, 2011 [31] | Subcutaneously 1.5 mg/kg/day | From the day of transfer to the day of hCG test, and if it was positive the treatment was continued for other 40 days | Normal saline               | Fresh ET  | NR         | NR                         | NR                           | NR                                |
criteria. A total of 77 records were further examined for eligibility, and 61 removed for non-RCT design (n = 52) or non-maternal administration route (n = 9). Finally, 16 articles were included into the stage of data extraction, then 4 excluded for duplicating data [24–27], 2 for logical error in published data [28, 29] and 1 without data regarding the IVF outcome. Finally, a total of ten studies were included in this meta-analysis [16–23, 30, 31].

With these ten articles published between 2000 and 2016, 1036 IVF-ET patients in all were randomized, from a wide range of regions including Europe [16, 18, 21, 31], North America [19] and Asia [17, 20, 22, 23, 30]. Among all studies, one evaluated the role of G-CSF treatment for unselected patients [19], one for the cases with thin endometrium [20], and remaining eight for those with RIF [16–18, 21–23, 30, 31]. The detailed characteristics of these studies are shown in Table 1.

### Meta-analysis

Ten studies all described the role of studied administration on CPR after ART. Figure 2a showed the forest plots RRs on CPR, and the pooled RR value was 1.89 (95% CI 1.53–2.33, \( P = 0.00 \)), indicating that G-CSF treatment may be beneficial to improve CPR in IVF-ET patients. Between studies homogeneity has been identified, as judged by the value \(I^2 (0.0\%)\). Four studies reported the data of embryo implantation [19, 22, 23, 25], and the pooled analysis did not show any beneficial effect of G-CSF treatment (RR 1.84, 95% CI 0.84–4.03, \( P = 0.13 \)) (Fig. 2b). The between-study variance was relatively high in this analysis \( (I^2 = 76.1\%)\). However, limited reports included in our study make it impossible to further examine the variance factors, such as meta-regression analysis.

Egger regression test of the data of CPR and IR did not find any significance (\( P = 0.45 \) and 0.24, respectively) and Begg’s funnel plot showed an evident balance, indicating a low chance of publication bias (Fig. S1). Figure S2 presents the result of influence analysis after removal of individual studies, and none individual study was found to excessively influence the pooled effect for both CPR and IR analyses (Table 2).

Subgroup analysis was further carried out according to the route of G-CSF administration (subcutaneous injection \( n = 5 \), uterine infusion \( n = 5 \), and unknown = 1) and the indications of G-CSF administration (unselected fertility \( n = 1 \), thin endometrium \( n = 1 \), and RIF \( n = 8 \)). In the subgroup analysis by administration route, we found an increased CPR for both uterine infusion and subcutaneous injection, and the pooled RRs (95% CI) were 1.46 (1.04–2.05) and 2.23 (1.68–2.95), respectively (Fig. 3a). Among the studies reporting the outcome of IR, four focused on the routes of uterine infusion, and only one on the subcutaneous injection.

### Table 1 (continued)

| Author, year | Drug route/dose | Administration time | Protocol | Description of the control | Previous failure CSF/control | Good embryos transferred (%) CSF/control | Embryos transferred CSF/control |
|-------------|----------------|--------------------|---------|---------------------------|------------------------------|----------------------------------------|-------------------------------|
| Scarpellini F, 2012 [18] | Subcutaneously 60 mg/daily | From the day of transfer to the day of hCG test, and if it was positive the treatment was continued for other 40 days | Normal saline | Normal saline | Normal saline | NR | NR |
| Singh R, 2015 [20] | Intrauterine infusion 300 µg or 300 µg × 2 | The morning of hCG administration | Normal saline | Fresh ET | Normal saline | NR | NR |
| Würfel W, 2000 [16] | Systematically 300 µg or 300 µg × 2 | Systematically | Normal saline | On the day of ET | Normal saline | NR | NR |

© Springer
The subgroup analysis has failed to find an increased IR after G-CSF treatment via uterine infusion (Fig. 3b). The only study with route of subcutaneous injection identified a beneficial role of G-CSF on IR [17].

In the subgroup analysis by the indications of G-CSF administration, a higher PR and IR has been found for G-CSF group as compared to the control after pooled analysis of RIF subjects, with the RRs (95% CI) 2.07 (1.64–2.61) and 1.52 (1.08–2.14), respectively. For unselected fertility or thin endometrium, only one study has been reported, and none improved PR or IR suggested for any population [19, 20].

Discussion

To date, bulks of studies have explored the benefit of G-CSF therapy for cases with RIF or unresponsive thin endometrium, or unselected patients. However, few conclusive answers can be drawn from these reports, partly due to the modest sample size, heterogeneity of administration indications or included subjects, study design, or ethnicity. Therefore, a meta-analysis is expected to provide us with more reliable and comprehensive results (Fig. 4).

Previous pooled analysis have suggested that G-CSF administration may do some good for clinical outcomes after ART treatment, however, it is still unclear which specific conditions of infertility or through which administration route does the G-CSF treatment play an beneficial role. Zhao et al. first reported the meta-analysis on this topic [32], and found an improvement in PR after G-CSF administration for infertile cases with RIF and thin endometrium, while none change in IR. Additionally, it seems that only via subcutaneous route can G-CSF administration play its beneficial role, which is contrast to the conclusion by Xie et al. [33] that only through local perfusion can G-CSF treatment improve the clinical outcome (including endometrial thickness, clinical pregnancy rate, and embryo implantation rate) after ART treatment. Another inconsistence existed in the effect of increasing endometrial thickness, while Xie et al. [33] found a statistical significance, Li et al. [34] failed to get this findings, despite that both analyses show an obvious improvement in the clinical outcome.

After quality evaluation of previous meta-analysis, it can be found that studies included for pooled analysis involved in a broad range of designs, of which the observational is the majority. Case control, cohort study, or case analysis may incur relatively greater selective bias, report bias, or confounding as compared to that of RCT. This might impair the robustness of these pooled analyses, and result in the inde terminacy in conclusion as mentioned above. Well-designed RCTs have a stronger power to control considerable biases above, and may supply a relative robust outcome. Unfortunately, the disputes still remained among available data from single RCT.

Our analysis took on a total of 10 RCTs between 2000 and 2016, involving 1016 IVF-ET cycles (521 distributed to G-CSF group, and 495 to the control), with the average ages between 31 and 39 years. From this analysis, we can conclude that G-CSF administration is able to significantly improve the CPR in total population, but it unexpectedly does not do any good for embryo implanting, the same result to the study of Zhao et al. [32]. The paradox between the roles on CPR and IR can be explained by the limited number...
| Study                | Selection bias | Performance and detection bias | Attrition bias | Selective reporting | Other bias |
|---------------------|----------------|--------------------------------|----------------|---------------------|-----------|
|                     | Risk | Explanation | Risk | Explanation | Risk | Explanation | Risk | Explanation | Risk | Explanation |   |
| Aleyasin A, 2016 [25] | L    | A computer-generated randomization table was used. | H    | No blinding | L    | No loss of follow-up | L    | Not suspected | L    | None |   |
| Barad DH, 2014 [19]  | L    | A computer-generated randomization table was used | L    | Study group was blinded to patients, physicians and nurses | L    | No loss of follow-up | L    | Not suspected | L    | None |   |
| Davari Tanha F, 2016 [23] | L    | A computer-generated randomization table was used | L    | Study group was blinded to patients and clinician | L    | No loss of follow-up | L    | Not suspected | L    | None |   |
| Eftekhari M, 2016 [22] | L    | Randomization with enveloped pocket method | H    | No blinding | L    | No loss of follow-up | L    | Not suspected | L    | None |   |
| Kim CH, 2011 [30]    | U    | Method of random sequence allocation was not described | U    | Method of blinding was not described | L    | No loss of follow-up | H    | Did not report implantation rate | H    | Meeting abstract | |
| Obidniak D, 2016, part I [21] | U    | Method of random sequence allocation was not described | U    | Method of blinding was not described | L    | No loss of follow-up | H    | Did not report implantation rate | H    | Meeting abstract | |
| Singh R, 2015 [20]   | L    | A computer-generated randomization table was used | U    | Method of blinding was not described | L    | No loss of follow-up | H    | Did not report implantation rate | H    | Meeting abstract | |
| Scarpellini F, 2011 [31] | U    | Method of random sequence allocation was not described | U    | Method of blinding was not described | L    | No loss of follow-up | H    | Did not report implantation rate | H    | Meeting abstract | |
| Scarpellini F, 2012 [18] | U    | Method of random sequence allocation was not described | U    | Method of blinding was not described | L    | No loss of follow-up | H    | Did not report implantation rate | H    | Meeting abstract | |
| Würfel W, 2000 [16]  | U    | Method of random sequence allocation was not described | U    | Method of blinding was not described | L    | No loss of follow-up | H    | Did not report implantation rate | H    | Meeting abstract | |

*U* unclear, *H* high, *L* low
of included studies reporting IR data (n = 4). Moreover, a significant between-study heterogeneity existed in IR analysis, and was difficult to be traced due to too few studies included (n < 5). Therefore, we must be still cautious to deal with the conclusion regarding the role on IR. To the best of our knowledge, this is the first meta-analysis pooling the data from RCTs which investigate whether G-CSF does any good for IVF patients.

We also conducted a subgroup analysis by drug route and indication of G-CSF treatment, two important factors that should be considered emphatically. The pooled analysis sub-grouped by drug route came to a conclusion that both systematic administration and local perfusion of G-CSF be beneficial for ART treatment, which is partly inconsistent with Zhao et al.’s findings [32] that uterine infusion be not an efficient route of G-CSF administration. However, another meta-analysis by Xie et al. [33] support our viewpoint that intrauterine administration can improve the clinical outcome after embryo transfer. Through more detailed comparison, it can be believed that the conclusion of our and Xie’s analysis may be more reliable due to more studies

Fig. 3 Forest plot comparing the effect of G-CSF on CPR (a) and IR (b) in infertile women undergoing IVF/ICSI for different routes of administration. Horizontal lines indicate 95% CIs; boxes show the study-specific weight; diamond represents combined effect size; dashed line indicates the overall estimate

Fig. 4 Forest plot comparing the effect of G-CSF on CPR (a) and IR (b) in infertile women undergoing IVF/ICSI for different indications of administration. Horizontal lines indicate 95% CIs; boxes show the study-specific weight; diamond represents combined effect size; dashed line indicates the overall estimate
included and more strict inclusion criterion on study design or patient type.

Among all RCTs included in our analysis, most were aimed at the cases with RIF (n = 8) and suggested a substantial efficiency of G-CSF treatment after pooled analysis, while only one at thin endometrium or unselected patients in each, and neither find the beneficial effect of GSF treatment. As to the cases with thin endometrium, two previous pooled analyses have indicated that these patients may benefit from G-CSF administration, however, almost all data were derived from observational studies, and the evidence not robust enough [33, 34]. Therefore, more RCTs are still needed to clear the therapeutic effect of G-CSF on thin endometrium cases.

To data, though various therapeutic propositions for G-CSF have already been reported, the specific molecular pathways of its endometrial and embryonic action have not yet been clear. It is generally accepted that establishment and maintenance of an intrauterine immune tolerance is an integral part of maternal–fetal interface, which is requisite for successful embryo implantation [35]. The mechanism underlying this immunotolerance involved a T cell helper 2 (Th-2) dominant state and Treg cell proliferation [35–37]. G-CSF has been proven as a novel mediator of T cell tolerance to target at Th-2 and Treg cell [38] and play a critical role in regulation of the intrauterine immunotolerance [12, 39]. Despite limited evidence, regulating embryo development and endometrial vascular remodeling may be another two physiological roles of G-CSF as suggested by an in vitro blastocyst formation and endometrial ex vivo model test, respectively [13, 14]. Nevertheless, all above proof is just weak and preliminary, and most solitary, and increasing fundamental knowledge is expected to support the clinical applications of G-CSF in reproductive medicine.

Totally, this study is the first meta-analysis based on RCTs dealing with the role of G-CSF administration on clinical outcomes after embryo transfer. And we think the results are reliable as showed by the sensitivity and influence analysis. In conclusion, both systematic administration and local perfusion of G-CSF play a beneficial role in ART treatment, especially for the cases with RIF, but its role on the thin endometrium remains blur because insufficient data on these cases can be retrieved. Additionally, a little data about the rate of live birth can be extracted from included studies, which may impair the convincingness of this analysis.

Acknowledgements This study was supported by the Natural Science Foundation of Zhejiang Province (LY15H260004 to L. Z., LY17H040014 to J. S. and LQ18H040004 to J. Z.), Zhejiang Medical and Health Science and Technology Plan Project (2014ZDA004 to L.Z.), National Natural Science Foundation of China (no. 81001260 to L. Z.), ‘New Century 151 Talent Program’ of Zhejiang Province (L. Z.).

Author contributions LZ: protocol/project development and manuscript editing; WHX: project development and data collection; XHF: data collection and data analysis; QXH: data collection and data analysis; XYG: data management; LZ: project development; SSL: project development; JZ: data management and manuscript writing; JS: protocol development, manuscript writing and editing.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Davidson LM, Coward K (2016) Molecular mechanisms of membrane interaction at implantation. Birth Defects Res C Embryo Today 108:19–32
2. Margaliot EJ, Ben-Chetrit A, Gal M, Eldar-Geva T (2006) Investigation and treatment of repeated implantation failure following IVF-ET. Hum Reprod 21:3036–3043
3. Cha J, Sun X, Dey SK (2012) Mechanisms of implantation: strategies for successful pregnancy. Nat Med 18:1754–1767
4. Simon A, Laufer N (2012) Repeated implantation failure: clinical approach. Fertil Steril 97:1039–1043
5. Cakmak H, Taylor HS (2011) Implantation failure: molecular mechanisms and clinical treatment. Hum Reprod Update 17:242–253
6. Nimikar-Joshi S, Rosario G, Katkam RR, Manjramkar DD, Metkari SM, Puri CP et al (2009) Embryo-induced alterations in the molecular phenotype of primate endometrium. J Reprod Immunol 83:65–71
7. Metcalf D (1985) The granulocyte—macrophage colony stimulating factors. Cell 43:5–6
8. Würfel W (2015) Treatment with granulocyte colony-stimulating factor in patients with repetitive implantation failures and/or recurrent spontaneous abortions. J Reprod Immunol 108:123–135
9. Zhao Y, Rong H, Chegini N (1995) Expression and selective cellular localization of granulocyte-macrophage colony-stimulating factor (GM-CSF) and GM-CSF alpha and beta receptor messenger ribonucleic acid and protein in human ovarian tissue. Biol Reprod 53:923–930
10. Giacomini G, Tabibzadeh SS, Satyaswaroop PG, Bonsi L, Vitale L, Bagnara GP et al (1995) Epithelial cells are the major source of biologically active granulocyte macrophage colony-stimulating factor in human endometrium. Hum Reprod 10:3259–3263
11. Salmassi A, Schmutzler AG, Huang L, Hedderich J, Jonat W, Mettler L (2004) Detection of granulocyte colony-stimulating factor and its receptor in human follicular luteinized granulosa cells. Fertil Steril 81(Suppl 1):786–791
12. Uzumaki H, Okabe T, Sasaki N, Hagiwara K, Takaku F, Tobita M et al (1989) Identification and characterization of receptors
for granulocyte colony-stimulating factor on human placenta and trophoblastic cells. Proc Natl Acad Sci USA 86:9323–9326
13. Cai L, Jeon Y, Yoon JD, Hwang S-U, Kim E, K-m Park et al (2015) The effects of human recombinant granulocyte-colony stimulating factor treatment during in vitro maturation of porcine oocyte on subsequent embryonic development. Theriogenology 84:1075–1087
14. Rahmati M, Petitbarat M, Dubanchet S, Bensussan A, Chaouat G, Ledee N (2014) Granulocyte-colony stimulating factor related pathways tested on an endometrial ex vivo model. PLoS One 9:e102286
15. Salmassi A, Schmutzler AG, Schaefer S, Koch K, Hedderich J, Jonat W et al (2005) Is granulocyte colony-stimulating factor level predictive for human IVF outcome? Hum Reprod 20:2434–2440
16. Würfel W (2000) Approaches to a better implantation. J Assist Reprod Genet 17:473
17. Aleyasin A, Abediasl Z, Nazari A, Sheikh M (2016) Granulocyte colony-stimulating factor in repeated IVF failure, a randomized trial. Reproduction 151:637–642
18. Scarpellini F, Sbracia M (2012) G-CSF treatment improves IVF outcome in women with recurrent implantation failure in IVF. J Reprod Immunol 94:103
19. Barad DH, Yu Y, Kushnir VA, Shohat-Tal A, Lazzaroni E, Lee HJ et al (2014) A randomized clinical trial of endometrial perfusion with granulocyte colony-stimulating factor in in vitro fertilization cycles: impact on endometrial thickness and clinical pregnancy rates. Fertil Steril 101:710–715
20. Singh R, Singh M, Jindal A, Jindal PC (2015) A prospective randomized controlled study (RCT) of intra-uterine administration of Granulocyte Colony-Stimulating Factor (G-CSF) before embryo-transfer on resistant thin endometrium in IVF cycles. Hum Reprod 30:1280
21. Obidniak D, Gzgzyan A, Dzhemlikhanova L, Feoktistov A (2016) Effect of colony-stimulating growth factor on outcome of frozen-thawed embryo transfer in patients with repeated implantation failure. Fertil Steril 106:e134–e135
22. Eftekhar M, Miraj S, Mojtahedi MF, Neghab N (2016) Efficacy of intrauterine infusion of granulocyte colony stimulating factor on patients with history of implantation failure: a randomized control trial. Int J Reprod BioMed 14:687–690
23. Davari-Tanha F, Tehraninejad ES, Ghazi M, Shahraki Z (2016) The role of G-CSF in recurrent implantation failure: a randomized double blind placebo control trial. Int J Reprod BioMed 14:737–742
24. Barad DH, Kushnir VA, Shohat-Tal A, Lazzaroni E, Lee HJ, Gleicher N (2013) Prospective randomized study of endometrial perfusion with granulocyte colony-stimulating factor (G-CSF) in unselected IVF cycles: impact on endometrial thickness and clinical pregnancy rates. Fertil Steril 100:S144
25. Abedi Asl Z (2015) The efficacy of systemic administration of granulocyte colony stimulating factor (GCSF) on the in vitro fertilization (IVF) success in women with repeated implantation failure. Fertil Steril 104:e61
26. Miraj S, Eftekhar M, Farid Mojtahedi M (2015) Efficacy of transvaginal perfusion of granulocyte colony stimulating factor on recurrent implantation failure: randomized control trial. Iran J Reprod Med 13:16
27. Eftekhar M, Sayadi M, Arabjahvani F (2014) Transvaginal perfusion of G-CSF for infertile women with thin endometrium in frozen et program: a nonrandomized clinical trial. Iran J Reprod Med 12:661–666
28. Scarpellini F, Sbracia M (2013) G-CSF treatment in the implantation failure with a fixed dose of 60 mcg/day: preliminary data of a controlled trial. Hum Reprod 28:1145–1146
29. Eftekhar M, Hosseinisadat R, Baradaran R, Naghshineh E (2016) Effect of granulocyte colony stimulating factor (G-CSF) on IVF outcomes in infertile women: an RCT. Int J Reprod BioMed 14:341–346
30. Kim CH, You RM, Nah HY, Kang HJ, Kim S, Chae HD et al (2011) Effect of granulocyte colony-stimulating factor on pregnancy outcome following IVF/ICSI in patients with repeated implantation failure. Hum Reprod 26:1244
31. Scarpellini F, Sbracia M (2011) Granulocyte colony-stimulating factor for the treatment of recurrent miscarriage. J Reprod Immunol 90:158–159
32. Zhao J, Xu B, Xie S, Zhang Q, Li YP (2016) Whether G-CSF administration has beneficial effect on the outcome after assisted reproductive technology? A systematic review and meta-analysis. Reprod Biol Endocrinol 14:62
33. Xie Y, Zhang T, Tian Z, Zhang J, Wang W, Zhang H et al (2017) Efficacy of intrauterine perfusion of granulocyte colony-stimulating factor (G-CSF) for infertile women with thin endometrium: a systematic review and meta-analysis. Am J Reprod Immunol, https://doi.org/10.1111/aji.12701
34. Li J, Mo S, Chen Y (2017) The effect of G-CSF on infertile women undergoing IVF treatment: a meta-analysis. Syst Biol Reprod Med 63:239–247
35. Achache H, Revel A (2006) Endometrial receptivity markers, the journey to successful embryo implantation. Hum Reprod Update 12:731–746
36. Saito S, Shima T, Nakashima A, Shiozaki A, Ito M, Sasaki Y (2007) What is the role of regulatory T cells in the success of implantation and early pregnancy? J Assist Reprod Genet 24:379–386
37. Franasiak JM, Scott RT (2017) Contribution of immunology to implantation failure of euploid embryos. Fertil Steril 107:1279–1283
38. Rutella S, Zavala F, Danese S, Kared H, Leone G (2005) Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol 175:7085–7091
39. Rahmati M, Petitbarat M, Dubanchet S, Bensussan A, Chaouat G, Ledee N (2015) Colony stimulating factors 1, 2, 3 and early pregnancy steps: from bench to bedside. J Reprod Immunol 109:1–6